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Attention Deficit Hyperactivity Disorder (ADHD) is the name given to a condition characterised by 
inattention, hyperactivity, and impulsivity. Although there are many historical descriptions of these 
behaviours in children1, definitions of ADHD as a disease emerged in the 1980s, when the practice of 
classifying mental disorders became popular and the DSM-III and ICD-9 diagnostic systems shifted 
the scientific focus on mental illness from aetiological debates to finding practical and reliable 
disease descriptions.  
The term ADHD, drawn from the DSM-III, was initially used only in North America. In Europe, the 
term ‘hyperkinetic disorder’ was used and was initially reserved only in the most severe cases. The 
broader definition afforded by the DSM eventually led to a corresponding rise in diagnosis rates in 
Europe, although they were still dwarfed by the much higher rates seen in the US. This historic 
diversion in practice has been partly explained by differing diagnostic criteria, but also by the power 
of the pharmaceutical industry, advocacy groups, and the internet2.  A comprehensive 2015 meta-
analysis included 175 ADHD prevalence studies and suggested an overall pooled estimate of 7.2%, 
although few included studies were from outside of Europe and North America3. 
Prescribing rates are naturally closely linked to prevalence and have also received much attention. A 
2016 study explored prescribing patterns of ADHD drugs in children in the UK using primary care 
records, finding a dramatic increase in use from 1992 until around 2008, with stable levels of use 
since then4. Indeed, ADHD drug use in children under 16 increased a staggering 34-fold overall in 
that 16-year period. The steadying in 2008 coincides with an update of the NICE guideline that 
stipulated that “drug treatment is not indicated as the first-line treatment for all school-age children 
and young people with ADHD”5.   
Diagnosis of ADHD can be challenging as one or more of the core symptoms can be missing and 
presentations are often linked to problems in education or with the justice system. As well as the 
overlay with antisocial behaviour, there may also be concurrent mental health issues, which can be 
difficult to disentangle. Adults, meanwhile, may have learned to compensate after years of 
untreated symptoms, adding an additional layer of complexity to the diagnostic process. It is not 
uncommon for adult patients to present to their GP querying whether they may have undiagnosed 
ADHD6.  Indeed, with the DSM-5 including for the first time diagnostic criteria for diagnosing ADHD 
in adults7, ADHD is no longer a disease confined to childhood, and has acquired the status of a 
chronic condition which may encompass the patient’s lifespan.  
A key role of GPs is to conduct an initial assessment to determine the severity of the symptoms, and 
the impact on daily life. A discussion may then ensue about the merits of a referral to confirm a 
possible diagnosis. Following specialist assessment, GPs provide support for the patient and family, 
and can help with ongoing monitoring of problems between specialist review appointments8. As well 
as pharmacological treatments, group-based parent-training programs are an important part of 
ADHD management. Psychological treatments including cognitive behavioural therapy are also 
widely used, with group based treatments preferred for younger children and individual treatments 
preferred for older groups. GPs work with mental health and paediatric teams, as well as teachers 
and social workers to co-ordinate care in ADHD. 
In light of the apparently subjective nature of ADHD diagnostic criteria and the wide variation in 
diagnostic rates in different parts of the world, there has been much debate about whether ADHD is 
being under- or over-diagnosed. This debate has taken place in both the medical and psychological 
communities as well as in the public domain, notably through stories in the lay press. Perhaps 
unsurprisingly given the exceptionally high prevalence rates in the USA, the anxiety about 
overdiagnosis has been particularly fervent in America and has had support from a number of 
media, celebrity, and political commentators. However, these concerns have also been voiced by 
clinicians and academics from across the world, including from within the UK. Shifting definitions 
and commercial influences have been suggested as important drivers of this overdiagnosis and it has 
been noted that elevated medication costs, adverse events, and psychological harms are all 
potential consequences9. The argument for ADHD being underdiagnosed, meanwhile, has been less 
forceful and less public, arising primarily from groups within psychiatric community.  
Although ADHD medications should only be initiated in secondary care, GPs are the first point of 
contact for patients and families. They are both gatekeepers to specialist services and long term 
prescribers of ADHD medications. Families visit specialist services at regular, defined intervals but 
tend to see their GPs during key moments of crisis. Given the public controversy about ADHD and 
particularly, its drug treatments, it is important for GPs to be well equipped to effectively counsel 
families who are often making difficult decisions about whether to persist with treatments. 
Shared decision making is one of the most important concepts in clinical medicine and is part of the 
essence of high quality general practice10. It requires clinicians to acknowledge both their own values 
and the limitations of medical science. By ascertaining the values of patients and providing them 
with accessible and reliable information based on clinical evidence, treatment decisions can be taken 
jointly and GPs can provide care that is inclusive, balanced and compassionate. 
Research that describes the experiences of patients in particular groups or settings can help 
clinicians gain deeper insight into the issues that matter most to patients and has the potential 
therefore to help them share decisions in a more effective way. The research used to gain these 
insights, though, typically employ qualitative methodologies and are therefore rarely referred to in 
clinical practice guidelines.  
In a recently published systematic review11, 31 such studies that investigated medication taking in 
ADHD patients and their carers were synthesised. It highlighted a complex array of factors that 
contribute to decisions about whether to take medications, including acceptance of the diagnostic 
label, anticipated and actual side effects of medications, and the external influences of school, 
friends, and the media. Self management was a particularly important theme and the decision-
making process tended to evolve as child patients enter adulthood and move towards autonomy. A 
further key theme was the concept of ‘trade offs’, as families described having to weigh up the 
numerous positive and negative consequences of medications on various aspects of their lives. 
As well as providing a rich account of issues that may need discussion in consultations about ADHD 
prescriptions, this systematic review emphasises the importance of understanding patient 
experience when making treatment decisions. Although clinical research provides us with invaluable 
information that helps guide treatment options, social science research can be equally helpful in 
highlighting the real world complexity of being a clinician or patient.  
The 2008 NICE guidance is under review and a draft recommendation is currently open for 
consultation12.  The revised guidance – due for publication in 2018 – is much more explicit in 
outlining strategies for sharing decisions relating to ADHD management: there is more focus on 
involving families, more specific recommendations on conversations around medication adherence, 
as well as proactive encouragement to discuss patient preferences around discontinuing or changing 
medication. The role of The GP remains one of supporting referral to specialist services for diagnosis 
and treatment, and to offer support, monitoring and advice. 
In many ways, ADHD is a disease for the 21st century. It provides column inches, fierce debates, 
polarised opinions, celebrity activism, information overload, and sadly, much confusion for patients 
and their families. It also demonstrates the role of the 21st century clinician – to provide balanced 
and informed counsel and facilitate a shared decision making process in all consultations. Clearly, 
specialist services will play an important part in deciding which patients are suitable for drug 
therapy, but in their role as holistic and kind patient advocates, GPs can play a key role in helping 
families to make sense of diagnostic and treatment uncertainties and make decisions that work best 
for them at that particular moment in their lives.  
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